Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection.
作者信息
Pallett Scott J C, Wake Rachel, Youngs Jonathan, Pope Cassie, Tan Ngee Keong, Taylor Joshua, Hawkins Lois, Witney Adam A, Laing Kenneth G, Monahan Irene M, Akay Melek, Cox Alison, Groppelli Elisabetta, Kelleher Peter, Miller Paul, Bicanic Tihana
机构信息
Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK.
Centre of Defence Pathology, Royal Centre for Defence Medicine, Edgbaston, Birmingham, UK.
出版信息
Br J Haematol. 2022 Mar;196(5):1170-1174. doi: 10.1111/bjh.17957. Epub 2021 Nov 11.
Abstract
摘要
相似文献
1
Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection.辅助性病毒细胞培养有助于指导继发体液免疫缺陷和持续感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者的治疗决策。
Br J Haematol. 2022 Mar;196(5):1170-1174. doi: 10.1111/bjh.17957. Epub 2021 Nov 11.
2
Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.关于“利妥昔单抗治疗患者的新型冠状病毒2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信
Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.
3
Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient.免疫功能低下患者中 SARS-CoV-2 的病毒持续排出。
J Infect Chemother. 2021 Feb;27(2):387-389. doi: 10.1016/j.jiac.2020.12.001. Epub 2020 Dec 4.
4
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.接受CAR T细胞疗法治疗的患者接种一剂和/或两剂BNT162b2抗SARS-CoV-2 mRNA疫苗后的安全性和抗体反应。
Br J Haematol. 2022 Jan;196(2):360-362. doi: 10.1111/bjh.17818. Epub 2021 Sep 2.
5
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.接受B细胞耗竭免疫疗法治疗的非霍奇金淋巴瘤患者感染新冠病毒后住院时间延长且死亡率更高。
Am J Hematol. 2021 Aug 1;96(8):934-944. doi: 10.1002/ajh.26209. Epub 2021 May 12.
6
Management of vaccinations in patients with non-Hodgkin lymphoma.非霍奇金淋巴瘤患者的疫苗接种管理。
Br J Haematol. 2024 May;204(5):1617-1634. doi: 10.1111/bjh.19422. Epub 2024 Mar 26.
7
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
8
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.COVID-19 与多发性骨髓瘤：从短期和长期来看多发性骨髓瘤患者对 SARS-CoV-2 的细胞和体液免疫。
J Mol Med (Berl). 2022 Mar;100(3):463-470. doi: 10.1007/s00109-021-02114-x. Epub 2021 Oct 18.
9
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.分析 PD-1/PD-L1 抑制剂联合或不联合化疗治疗的癌症患者全程接种 BNT162b2 抗 SARS-CoV-2 疫苗后的体液和细胞免疫应答：6 个月随访后的更新。
ESMO Open. 2022 Feb;7(1):100359. doi: 10.1016/j.esmoop.2021.100359. Epub 2021 Dec 11.
10
Long-term follow-up of recovered MPN patients with COVID-19.新冠病毒感染康复的骨髓增殖性肿瘤患者的长期随访
Blood Cancer J. 2021 Jun 16;11(6):115. doi: 10.1038/s41408-021-00509-0.
引用本文的文献
1
Immunocompromised Patients with Protracted COVID-19: a Review of "Long Persisters".患有持续性新冠病毒感染的免疫功能低下患者：“长期感染者”综述
Curr Transplant Rep. 2022;9(4):209-218. doi: 10.1007/s40472-022-00385-y. Epub 2022 Nov 12.
本文引用的文献
1
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study.与 SARS-CoV-2 变体 B.1.1.7 相关的症状学变化、再感染和传染性：一项生态学研究。
Lancet Public Health. 2021 May;6(5):e335-e345. doi: 10.1016/S2468-2667(21)00055-4. Epub 2021 Apr 12.
2
COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire.COVID-19 和与 HIV 相关的免疫重建炎症综合征：病原体特异性免疫反应的出现，火上浇油。
Front Immunol. 2021 Mar 24;12:649567. doi: 10.3389/fimmu.2021.649567. eCollection 2021.
3
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection.血液透析患者中SARS-CoV-2免疫反应的持久性及对再次感染的防护
Kidney Int. 2021 Jun;99(6):1470-1477. doi: 10.1016/j.kint.2021.03.009. Epub 2021 Mar 25.
4
Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).针对新型冠状病毒肺炎（COVID-19）患者细胞因子风暴的免疫调节治疗策略（综述）
Exp Ther Med. 2021 Apr;21(4):319. doi: 10.3892/etm.2021.9750. Epub 2021 Feb 3.
5
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对单剂量BNT162b2疫苗体液和T细胞反应的影响
Lancet. 2021 Mar 27;397(10280):1178-1181. doi: 10.1016/S0140-6736(21)00502-X. Epub 2021 Feb 25.
6
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.血液系统恶性肿瘤和医院内传播与 COVID-19 死亡风险增加相关：来自英国多中心队列的研究结果。
Leuk Lymphoma. 2021 Jul;62(7):1682-1691. doi: 10.1080/10428194.2021.1876865. Epub 2021 Jan 28.
7
Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?在新冠疫情时代，是否需要重新考虑在异基因造血细胞移植后使用 G-CSF？
Br J Cancer. 2021 Mar;124(7):1183. doi: 10.1038/s41416-020-01195-8. Epub 2021 Jan 4.
8
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report.瑞德西韦治疗无体液免疫的 COVID-19：一例报告。
Nat Commun. 2020 Dec 14;11(1):6385. doi: 10.1038/s41467-020-19761-2.
9
Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?康复期 COVID-19 患者鼻拭子中的 SARS-CoV-2 RNA 残留：延长隔离是否总是合理？
Int J Infect Dis. 2021 Jan;102:299-302. doi: 10.1016/j.ijid.2020.10.072. Epub 2020 Oct 30.
10
Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.在致死性 COVID-19 患者中的病毒存在和免疫病理学：一项前瞻性尸检队列研究。
Lancet Microbe. 2020 Nov;1(7):e290-e299. doi: 10.1016/S2666-5247(20)30144-0. Epub 2020 Sep 25.
Zotero 插件